The past 12 months mark a milestone year for the discipline of sports and exercise cardiology.We have seen the publication of two major guideline documents for athletes: the 2025 American Heart Associ ...

India is witnessing a surge in innovative health tech solutions, from AI-powered remote health monitoring devices to smart ...

HeartBeam (NASDAQ: BEAT) , announced the issuance of two new U.S. patents that strengthen its intellectual property portfolio and support the company ...

HeartBeam’s credit card-sized device demonstrated 93.4% diagnostic agreement with standard ECGs VALID-ECG study results presented at Heart Rhythm Society conference Company eyes U.S ...

HeartBeam (NASDAQ: BEAT) announced its synthesized 12-lead ECG met clinical endpoints in the VALID-ECG pivotal study, achieving 93.4% diagnostic agreement with standard ECGs for arrhythmia assessment.

Milestone results formed the basis of HeartBeam’s 12-lead ECG synthesis software application submitted to FDA in January 2025 SANTA CLARA, Calif.-- (BUSINESS WIRE)-- HeartBeam, Inc., (NASDAQ: BEAT), a ...

Data showed a 93.4% overall diagnostic agreement, indicating that HeartBeam’s synthesized 12-lead ECG can support diagnosis of arrhythmias in a manner consistent with standard 12-lead ECGs.

Data from the VALID-ECG study formed the basis of HeartBeam’s FDA application for the 12-lead ECG synthesis software. The company submitted for approval in January 2025.

The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient’s 3-Lead (in three-directions) electrocardiogram (ECG) acquired from 5 electrodes.

The Company believes the study's findings support the clinical equivalence of HeartBeam's synthesized 12-lead ECG where the leads are similar to standard 12-lead ECGs for rhythm and arrhythmia ...